New York Ketamine Infusions provides medically supervised ketamine therapy in New York for adults being evaluated for depression, treatment-resistant depression (TRD), anxiety, PTSD, OCD, bipolar depression, alcohol dependence and other appropriate conditions.
With clinics in New York City (Manhattan) and Long Island (Melville), our medical team evaluates each patient individually to determine whether IV ketamine therapy, SPRAVATO® (esketamine), or another treatment pathway may be appropriate.
Ketamine therapy is the medically supervised use of ketamine for therapeutic purposes. In mental health care, IV ketamine has been studied most extensively for depression and treatment-resistant depression. Ketamine affects glutamate signaling differently from conventional antidepressants and may produce a rapid antidepressant response in some appropriately selected patients. Psychiatric use of IV ketamine is considered off-label.
Depression and treatment-resistant depression.
IV ketamine is administered in a medically supervised setting.
Every patient is screened before treatment is recommended.
Manhattan and Melville, Long Island.
Ketamine works differently from conventional antidepressants. One of its primary pharmacological actions is antagonism of the NMDA receptor, which is involved in the brain's glutamate signaling system.
Research suggests that downstream effects involving AMPA receptors and pathways associated with synaptic plasticity may contribute to ketamine's rapid antidepressant properties.
This different mechanism is one reason ketamine has become an important area of research for people whose depression has not adequately responded to conventional treatment.
Learn more about how ketamine works and why its mechanism differs from traditional antidepressants.
Depression and treatment-resistant depression represent the strongest areas of research supporting ketamine's psychiatric use. For some patients who have not experienced sufficient improvement with conventional treatment, ketamine provides a different therapeutic approach.
Major depressive disorder can affect mood, motivation, sleep, concentration, energy, relationships and daily functioning. Standard care may include psychotherapy, antidepressant medication and other evidence-based approaches.
Ketamine may be considered for appropriately selected patients, particularly when previous treatments have not provided sufficient relief.
Learn about ketamine treatment for depression →Treatment-resistant depression (TRD) generally describes depression that continues despite adequate attempts with conventional antidepressant treatments.
Ketamine has become particularly important in TRD research because some patients experience antidepressant effects considerably faster than is typical with conventional antidepressant medications.
Explore treatment-resistant depression treatment →The distinction is important when considering advanced treatment options such as IV ketamine or SPRAVATO®.
Depression can involve persistent sadness, loss of interest, low energy, changes in sleep or appetite, difficulty concentrating and other symptoms that interfere with daily life.
TRD describes depression that has not sufficiently improved despite appropriate treatment attempts. These patients may be evaluated for additional treatment strategies.
New York Ketamine Infusions evaluates adults with several mental health conditions. Evidence, treatment protocols and appropriateness differ by diagnosis, so treatment begins with an individualized medical assessment.
Ketamine has been extensively investigated for depression, particularly when symptoms have persisted despite previous treatment.
Depression treatment →Patients whose depression has not adequately responded to conventional treatment may be evaluated for advanced options.
Learn about TRD →Ketamine has been studied for certain severe or treatment-resistant anxiety symptoms. Individual evaluation is required.
Anxiety treatment →Research has explored ketamine's potential role in reducing symptoms associated with post-traumatic stress disorder.
PTSD treatment →Early research has investigated ketamine for some people with difficult-to-treat obsessive-compulsive disorder.
OCD treatment →Ketamine has been studied for bipolar depression. Careful psychiatric assessment is especially important because bipolar disorder can also involve mania or hypomania.
Bipolar treatment →Research has examined ketamine as one potential component of treatment for alcohol dependence within a broader recovery plan.
Alcohol dependence treatment →
There is no single diagnosis or checklist that automatically determines whether ketamine therapy is appropriate. Candidacy is determined through an individualized clinical evaluation.
A consultation may include review of:
IV ketamine is administered in a medically supervised clinical environment. Your individual treatment plan is determined by your provider based on your health history, diagnosis and response.
Your medical history, symptoms, medications and previous treatment response are reviewed.
An intravenous line allows the clinical team to administer ketamine according to the prescribed protocol.
You remain under clinical observation throughout treatment while your response and comfort are monitored.
Your response is assessed and subsequent treatment is individualized according to clinical need.
Learn more about medically supervised ketamine treatment at New York Ketamine Infusions and what patients can expect during the treatment process.
IV ketamine and SPRAVATO® are related treatments, but they differ in formulation, administration, FDA status for depression and insurance considerations.
Yes. Ketamine is an FDA-approved prescription medication that may legally be prescribed and administered by qualified healthcare professionals when medically appropriate.
IV ketamine's use for depression and other psychiatric conditions is considered off-label. Off-label prescribing refers to the use of an approved medication for an indication or manner not specifically included in its FDA-approved labeling.
Insurance coverage for IV ketamine used for psychiatric conditions is often limited because this use is off-label. Coverage varies by plan.
SPRAVATO® has FDA-approved depression indications and may have insurance benefits for eligible patients, subject to plan criteria and authorization requirements.
Learn about SPRAVATO® insurance coverage →New York Ketamine Infusions provides medically supervised treatment at two convenient New York locations: Lower Manhattan and Melville, Long Island.
New York Ketamine Infusions
160 Broadway, 16th Floor
New York, NY 10038
Phone: 917-261-7370
Our Manhattan clinic serves patients throughout New York City, including Lower Manhattan, the Financial District, Tribeca, SoHo, Brooklyn and surrounding communities.
New York Ketamine Infusions
150 Broadhollow Rd, Suite 103
Melville, NY 11747
Phone: 631-629-4626
Our Melville clinic serves patients throughout Long Island, including Huntington, Dix Hills, Farmingdale, Plainview, Bethpage, Deer Park and surrounding Nassau and Suffolk County communities.
If depression or another mental health condition has continued despite previous treatment, our clinical team can review your history and help determine whether IV ketamine, SPRAVATO®, or another treatment pathway may be appropriate.
Answers to common questions about ketamine treatment in New York.
Ketamine therapy is the medically supervised administration of ketamine for a therapeutic purpose. In mental health care, ketamine has been studied most extensively for depression and treatment-resistant depression. Psychiatric use of IV ketamine is off-label.
New York Ketamine Infusions evaluates adults with depression, treatment-resistant depression, anxiety, PTSD, OCD, bipolar depression, alcohol dependence and certain other concerns. Treatment appropriateness is determined individually.
Clinical research has demonstrated rapid antidepressant effects from ketamine in some people with depression, including treatment-resistant depression. Response and duration of improvement vary among patients.
Treatment-resistant depression generally refers to depression that has not sufficiently improved despite appropriate attempts with conventional antidepressant treatment. A clinician should review the patient's treatment history before determining whether TRD applies.
Ketamine has demonstrated antidepressant effects within hours in some clinical research participants. Not every patient responds, and individual treatment response cannot be predicted in advance.
Ketamine is FDA-approved as an anesthetic, but IV ketamine use for depression and other psychiatric conditions is off-label. SPRAVATO® (esketamine) has specific FDA-approved depression indications.
Yes. Ketamine is a prescription medication that qualified healthcare professionals can prescribe and administer when medically appropriate. Psychiatric use of IV ketamine is generally off-label.
Insurance coverage for IV ketamine used for psychiatric conditions is often limited and varies by plan. SPRAVATO® has FDA-approved indications and may be covered for eligible patients who meet their health plan's requirements.
New York Ketamine Infusions provides treatment at 160 Broadway, 16th Floor, New York, NY 10038 and at 150 Broadhollow Rd, Suite 103, Melville, NY 11747.
The first step is a clinical consultation. The medical team can review your symptoms, diagnosis, health history, medications and previous treatments to determine whether ketamine therapy may be appropriate.
Learn more from government and research sources about ketamine, depression and advanced depression treatment.
